Precigen, Inc. has reported a significant uptick in revenue driven by the launch of its new therapy, Papzimius, which gained full FDA approval for treating adult recurrent respiratory papillomatosis (RRP). The company recorded $3.4 million in net product revenue for fiscal Q4 2025, with projections for Q1 2026 revenue expected to exceed $18 million, reflecting strong initial uptake and expanding payer coverage, now reaching approximately 90% of insured lives in the U.S.
The rapid adoption of Papzimius is noteworthy, particularly as it marks a shift from surgical interventions to a therapeutic approach for RRP, a condition historically managed through repeated surgeries. The anticipated permanent J code for Papzimius, effective April 1, will further streamline reimbursement processes, potentially enhancing market penetration. Despite a reported net loss of $429.6 million, largely due to nonrecurring charges, the company’s cash position of $100.4 million, coupled with strong sales momentum, positions it for cash flow breakeven by 2026.
Market professionals should monitor Precigen’s performance closely, as the successful commercialization of Papzimius could set a precedent for future therapies in niche markets, particularly those with similar reimbursement challenges.
Source: fool.com